Anthrax is a serious illness caused by a spore-forming bacterium called Bacillus anthracis. The disease majorly affects wild game and livestock. However, humans can get infected by anthrax bacteria through direct or indirect contact with animals that carry it. The bacteria causing anthrax enters the human body through a wound in the skin. In addition, inhaling bacterial spores and eating contaminated meat can lead to infection. Signs and symptoms of anthrax include skin sores, fever, and vomiting. For the prevention of anthrax, a three-dose series of anthrax vaccines is used. Common types of anthrax vaccines include cell-free protective agent (PA) vaccines and live anthrax vaccines.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the anthrax vaccine market.
Top Impacting Factors
The anthrax vaccine market is expanding rapidly due to increase in prevalence of anthrax. Rise in trend of eating of raw and undercooked meat from infected animals acts as a major driver of the global market.
In addition, surge in manufacturing and industrial processing of contaminated animal materials such as hair wool and hide augments the market growth significantly.
Anthrax is majorly prevalent among wild game and livestock. With increase in animal husbandry across the globe, the number of farms is increasing. Individuals working in farms come in close proximity with animals, and hence are at high risk of developing anthrax. This factor acts as a key driving force of the market
However, anthrax disease has a low rate of voluntary screening and this can act as a major restraint for the growth of the anthrax vaccine market. In addition, lack of awareness about anthrax diagnostic tests in countries such as Africa makes it difficult for companies to reach their customers directly in such countries and regions, thereby hampering the market growth.
Key Market Trends
Hospital pharmacies in the distribution channel segment dominated the market. Hospitals act as a major site for vaccination, which is why the sale of anthrax vaccines is high there. Moreover, anthrax vaccines are part of the standard patient practices in hospitals.
The animal use segment led the anthrax vaccine market, as a high proportion of anthrax vaccines is used for animals. Up to 20% of anthrax cases in humans lead to death. Hence, this has led to the growth of the animal use segment.
Several Chinese manufacturers are involved in producing anthrax vaccines as per the increasing demands. Hence, setting up manufacturing units in China will help propel the mass production and distribution of these vaccines.
Top players of the anthrax vaccine market are Emergent BioSolutions, Colorado Serum, and Merck, Inc., as they hold patents and key technologies for anthrax vaccine development along with the high-end customer segments.
Key Benefits of the Report
- This study presents the analytical depiction of the anthrax vaccine industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the anthrax vaccine market share.
- The current market is quantitatively analyzed to highlight the growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Anthrax Vaccine Report
- Which are the leading players active in the anthrax vaccine market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the anthrax vaccine market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 in the industry?
- What is the anthrax vaccine?
- What is the anthrax vaccine market prediction in the future?
- What are the current trends and predicted trends?
Anthrax Vaccine Market Report Highlights
| Aspects | Details |
 By Vaccine Type |
|
 By Application |
|
 By End User |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Colorado Serum, Biogenesis Bago S.A., Merck & Co., Inc., Emergent Bio-Solutions, Merial, Inc., Altimmune (PharmAthene Inc.), Zoetis, Inc., Bayer AG, Porton Biopharma Limited, PharmAthene, Inc. |
Loading Table Of Content...
